Epithalon (Epitalon)

Rows are ordered by price per mg: listed price divided by stated peptide content, excluding shipping and codes, so every vial competes on the same axis. Each row carries its own $/mg figure, so the size of the gap between vendors is visible, not just the order. Sprays follow the vials, unranked.

The best-documented testing flag goes to the vendor publishing batch-level, third-party certificates. The shipping flag goes to the fastest published delivery from a domestic warehouse. Data is re-checked on a schedule and each row carries its verification date.

AEDG tetrapeptide (Epitalon) — the most-researched telomerase activator for longevity and senescence-focused.

A synthetic 4-residue peptide (Ala-Glu-Asp-Gly) characterised in the primary literature by the Khavinson group as a modulator of telomerase activity and pineal-gland gene expression in preclinical models. For laboratory characterisation only.

Epithalon is a synthetic tetrapeptide (AEDG) that activates telomerase via hTERT upregulation. A September 2025 Biogerontology study confirmed dose-dependent telomere extension in normal epithelial, fibroblast, and cancer cell lines. Brunel University (2025) independently replicated telomere lengthening across cell types. Additional 2025 data shows it restores antioxidant genes (SOD2, catalase, HO-1) and prevents DNA hypomethylation in hyperglycemic retinal cells.

What Epithalon (Epitalon) is

Epithalon (Epitalon) is a synthetic tetrapeptide (4 amino acids). Epithalon is a synthetic tetrapeptide (AEDG) that activates telomerase via hTERT upregulation. A September 2025 Biogerontology study confirmed dose-dependent telomere extension in normal epithelial, fibroblast, and cancer cell lines. Brunel University (2025) independently replicated telomere lengthening across cell types. Additional 2025 data shows it restores antioxidant genes (SOD2, catalase, HO-1) and prevents DNA hypomethylation in hyperglycemic retinal cells. It has a molecular formula C14H22N4O9, mass 390.35 Da. Its published amino-acid sequence is Ala-Glu-Asp-Gly. Common synonyms in the literature include Epitalon, Epithalone, and AEDG peptide.

Investigation of Epithalon (Epitalon) to date is primarily preclinical, with the majority of citations concentrated in animal models and in-vitro assays rather than randomized controlled human trials. Published work referencing Epithalon (Epitalon) spans Human cell culture studies: Research in human fetal lung fibroblasts, epithelial cells (HMEC, IBR.3), and lymphocytes has examined Epithalon's effects on telomerase activity and telomere length. Studies using the TRAP (Telomere Repeat Amplification Protocol) assay reported telomere extensions up to 33.3% on average in some lymphocyte studies, Telomerase gene expression: Experiments showed Epithalon upregulates hTERT (the catalytic subunit of telomerase) mRNA expression, with effects occurring primarily during the G1 phase of the cell cycle. The peptide reportedly enters cell nuclei and binds to promoter regions containing ATTTC motifs, and Cancer cell comparisons: In cancer cell lines (21NT, BT474, HeLa), Epithalon was observed to extend telomeres primarily through the ALT (Alternative Lengthening of Telomeres) pathway rather than telomerase activation, suggesting selectivity for healthy cells. This selectivity has been proposed as a safety feature. Proposed mechanisms in the literature include hTERT upregulation: increases telomerase catalytic subunit mRNA expression primarily during G1 cell cycle phase and Chromatin modification: enters cell nuclei, binds promoter regions (ATTTC motifs) for epigenetic activation. None of this material describes therapeutic outcomes in humans, and No vendor listed here provides dosing guidance for Epithalon (Epitalon) outside laboratory research.

For the full mechanistic profile, published references, and constraint notes on Epithalon (Epitalon), see the Epithalon (Epitalon) research page. All references cited on that page are peer-reviewed primary literature.

Binding and functional-assay data for Epithalon (Epitalon), from peer-reviewed in-vitro pharmacology publications. Values are receptor activity parameters — not clinical outcomes.

Study designs referencing this compound in the published literature. Descriptions cover framework only — phase, participant count, duration, and citation — not outcomes. Click a card to review the source directly.